meningoccal conjugate vaccine ACWY (Menveo)
Jump to navigation
Jump to search
Introduction
different vaccines for different serotypes
Indications
- prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135
- routine use in adolescents age 11- 12 years, with a booster at 16 years
- immunosuppressed* persons age 2-54 years
- 1st dose administered after age 16 years a booster is not required
- college freshmen living in resident halls should receive the vaccine within 5 years of enrollment
- all patients with HIV1 disease
- 2 dose schedule for patients > 2 years of age plus booster doses every 5 years[4]
* patients with terminal complement deficiency are at higher risk for meningococcal disease
- patients with immunoglobulin deficiency are not[2]
Notes
More general terms
More specific terms
Additional terms
Component of
References
- ↑ 1.0 1.1 Su JR, Miller ER, Duffy J et al Notes from the Field: Administration Error Involving a Meningococcal Conjugate Vaccine- United States, March 1, 2010- September 22, 2015. MMWR Weekly / February 19, 2016 / 65(6);161-162 http://www.cdc.gov/mmwr/volumes/65/wr/mm6506a4.htm
- ↑ 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ Cohn AC, MacNeil JR, Clark TA et al for the Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23515099 Free Article
- ↑ 4.0 4.1 MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep 2016;65:1189-1194 https://www.cdc.gov/mmwr/volumes/65/wr/mm6543a3.htm